ANIP Ani Pharmaceuticals Inc

Price (delayed)

$32.97

Market cap

$420.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.28

Enterprise value

$573.39M

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
The company's EPS rose by 32% QoQ
Ani Pharmaceuticals's net income has increased by 31% QoQ
ANIP's gross margin is down by 8% year-on-year but it is up by 3.1% since the previous quarter
The gross profit has grown by 5% since the previous quarter but it has declined by 4% year-on-year

Key stats

What are the main financial stats of ANIP
Market
Shares outstanding
12.74M
Market cap
$420.04M
Enterprise value
$573.39M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2
Price to sales (P/S)
1.86
EV/EBIT
N/A
EV/EBITDA
15.01
EV/Sales
2.69
Earnings
Revenue
$213.22M
EBIT
-$6.15M
EBITDA
$38.21M
Free cash flow
$28.93M
Per share
EPS
-$1.28
Free cash flow per share
$2.41
Book value per share
$16.47
Revenue per share
$17.74
TBVPS
$23.42
Balance sheet
Total assets
$463.84M
Total liabilities
$260.13M
Debt
$183.42M
Equity
$203.71M
Working capital
$100.03M
Liquidity
Debt to equity
0.9
Current ratio
2.21
Quick ratio
1.47
Net debt/EBITDA
4.01
Margins
EBITDA margin
17.9%
Gross margin
60%
Net margin
-7.2%
Operating margin
-2.9%
Efficiency
Return on assets
-3.3%
Return on equity
-7.9%
Return on invested capital
-1.8%
Return on capital employed
-1.6%
Return on sales
-2.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
-2.22%
1 week
-5.39%
1 month
-7.8%
1 year
9.32%
YTD
13.53%
QTD
-8.77%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$213.22M
Gross profit
$127.88M
Operating income
-$6.15M
Net income
-$15.45M
Gross margin
60%
Net margin
-7.2%
The company's operating income has surged by 63% QoQ
ANIP's operating margin has surged by 63% since the previous quarter
The net margin has increased by 33% QoQ
Ani Pharmaceuticals's net income has increased by 31% QoQ

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
2
P/S
1.86
EV/EBIT
N/A
EV/EBITDA
15.01
EV/Sales
2.69
The company's EPS rose by 32% QoQ
The P/B is 41% below the 5-year quarterly average of 3.4
The company's equity rose by 4.1% QoQ
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 3.8 but 3.3% higher than the last 4 quarters average of 1.8
Ani Pharmaceuticals's revenue has increased by 4.8% YoY and by 2.3% from the previous quarter

Efficiency

How efficient is Ani Pharmaceuticals business performance
The company's return on sales has surged by 63% QoQ
Ani Pharmaceuticals's ROIC has soared by 62% from the previous quarter
The ROA has grown by 31% from the previous quarter
The return on equity has grown by 31% since the previous quarter

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 78% more than its total liabilities
The company's current ratio rose by 11% YoY
ANIP's quick ratio is up by 8% year-on-year and by 7% since the previous quarter
The debt is 10% lower than the equity
The debt to equity has decreased by 9% YoY and by 5% from the previous quarter
The debt has decreased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.